Here are the 424B prospectus supplements from Attovia Therapeutics, Inc. (ATTO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ATTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATTO filings page.
Attovia Therapeutics, Inc. is conducting an initial public offering of 17,000,000 shares of common stock at $17.00 per share, for a gross offering of $289,000,000. Underwriters have a 30-day option to purchase up to 2,550,000 additional shares to cover over-allotments. Net proceeds are estimated at $265.1 million (or $305.4 million with full exercise), after underwriting discounts and estimated expenses.
The company is a clinical-stage biopharmaceutical developer of next‑generation biologics for immune‑mediated diseases, built on its proprietary ATTOBODY platform. Lead candidate ATTO-1310 is in a Phase 1 trial for chronic pruritic diseases; ATTO-2306 (bispecific IL‑13/IL‑31) and ATTO-1091 (trispecific TL1A/IL‑23/integrin α4β7) are in IND‑enabling studies with planned Phase 1 trials in the first half of 2027.
As of March 31, 2026, Attovia held $132.6 million in cash, cash equivalents and marketable securities and reported an accumulated deficit of $129.7 million, reflecting net losses of $39.8 million in 2024 and $60.6 million in 2025. The company qualifies as an emerging growth company and smaller reporting company and expects the IPO proceeds, together with existing cash, to fund operations into 2029.